Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.本發明揭示加巴潘定(gabapentin)前驅藥,1-{[(α-異丁醯氧基乙氧基)羰基]胺甲基}-1-環己烷乙酸,之持釋性口服劑型。該劑型可用於治療或預防可為加巴潘定(gabapentin)有效治療之疾病和失調症。